Active Ingredient History
Tucidinostat is a histone deacetylase inhibitor (HDI) developed in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 4)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 1/Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Cisplatin (Phase 2)
Colorectal Neoplasms (Phase 2)
Cyclophosphamide (Phase 2)
Dexamethasone (Phase 2)
Drugs, Investigational (Phase 2)
Epigenetic Repression (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Genetic Diseases, Inborn (Phase 2)
Herpesvirus 4, Human (Phase 2)
Histone Deacetylase Inhibitors (Phase 2)
HIV Infections (Phase 2/Phase 3)
Hodgkin Disease (Phase 2)
Immune Checkpoint Inhibitors (Phase 2)
Immune System Diseases (Phase 2)
Immunoproliferative Disorders (Phase 2)
Leukemia (Phase 2/Phase 3)
Leukemia, B-Cell (Phase 2/Phase 3)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Promyelocytic, Acute (Phase 2)
Leukemia, T-Cell (Phase 2/Phase 3)
Lymphatic Diseases (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 4)
Lymphoproliferative Disorders (Phase 2)
Melanoma (Phase 3)
Mental Disorders (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2)
Neuroblastoma (Phase 1)
Neuroendocrine Tumors (Phase 2)
Osteosarcoma (Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2/Phase 3)
Recurrence (Phase 1/Phase 2)
Rituximab (Phase 2)
Sarcoma (Phase 2)
Thrombocytopenia (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue